Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2022 16:01 ET | Source: Roivant Sciences

Roivant Sciences Announces Proposed Public Equity Offering

BASEL, Switzerland, LONDON, NEW YORK, and BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the...
October 18, 2022 16:00 ET | Source: Roivant Sciences

Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences

Investor call and webcast scheduled for Monday, November 14 at 8:00 a.m. ESTRoivant will present at investor conferences in November BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Oct. ...
August 30, 2022 07:00 ET | Source: Roivant Sciences

Roivant to Participate in September Investor Events

Three healthcare investor conferences in September across Boston, New York and LondonRoivant Investor Day will take place virtually on September 28th starting at 11 a.m. EDT BASEL, Switzerland and...
August 15, 2022 07:00 ET | Source: Roivant Sciences

Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update

Early launch data for VTAMA® (tapinarof) with approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of launch shows strong demand for first topical...
August 03, 2022 07:00 ET | Source: Roivant Sciences

Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

Investor call and webcast scheduled for Monday, August 15 at 8:00 a.m. EDTRoivant will host an investor day on Wednesday, September 28 at 11:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and...
June 28, 2022 06:10 ET | Source: Roivant Sciences

Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years;...
June 28, 2022 06:00 ET | Source: Roivant Sciences

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant...
June 15, 2022 16:30 ET | Source: Roivant Sciences

Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022

Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a...
May 24, 2022 06:00 ET | Source: Roivant Sciences

FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years

- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician...
May 19, 2022 16:30 ET | Source: Roivant Sciences

Roivant to Present at Upcoming Investor Conferences

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences: UBS Global...